$PLSE

Teplitsky Liane Rae purchased $100K of PLSE

Teplitsky Liane Rae (Chief Operating Officer) purchased 2,070 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $48.29 ($48.24–$48.35) across 2 trades over 2026-08-26 to 2026-08-28.

Original reporting
SEC EDGAR · Teplitsky Liane Rae
Published Aug 28, 2026, 11:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PLSE
Neutral
medium confidence
Mentioned
$PLSE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLSENeutralLow
01

Why it matters

The disclosed purchase is modest and unlikely to move the stock significantly, but it adds to the insider activity record.

02

Market read

Limited relevance; adds a data point to insider activity monitoring.

03

What to watch

Potential upcoming clinical trial milestones that may have prompted the insider to increase stake.

Relevance 4/10Novelty 3/10Timing: reported after market close on 2026-08-28

Background

Form 4 filings disclose insider transactions; investors monitor them for signals of insider confidence.

Company-level read

Ticker impact

$PLSENeutralMedium confidence
Context

COO Teplitsky Liane Rae bought 2,070 shares of Pulse Biosciences for $99,965, a direct insider purchase disclosed on Form 4.

Expected impact

Minor upward pressure, likely within normal volatility range.

Evidence & confidence

Purchase amount is under $100k and represents a tiny fraction of float; while insider buying is positive, the scale does not suggest a material shift.

Market effects

Minimal effect on biotech sector; typical insider activity.

No regional impact.

Not globally relevant.

Counterpoint

The purchase could be a routine compensation exercise rather than a confidence signal.

Key entities

  • Pulse Biosciences, Inc.

    Biotech firm developing cell-based therapies.

  • Teplitsky Liane Rae

    Chief Operating Officer of Pulse Biosciences.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PLSEMedAI 8/10

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) reported Q2 2026 revenue of $434,000 and GAAP net loss of $24.7 million. Cash and equivalents rose to $101.6 million by June 30, 2026 after $57.5 million in ATM proceeds. NANOPULSE-AF enrollment exceeded halfway with early October completion target; CE Mark for the catheter expected in 2H 2026.

$PLSEMed

PULSE BIOSCIENCES, INC. (PLSE): Results of Operations and Financial Condition

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-P

$LTHMedAI 8/10

Green LTF Holdings II LP sold $126.1M of LTH

Green LTF Holdings II LP sold 2,879,154 shares of Life Time Group Holdings, Inc. (LTH) at $43.80 ($126.11M total) across 3 trades on 2026-08-26. Filed jointly with GEI Capital VI, LLC (Director), Green Equity Investors Side VI, L.P. (Director), Green Equity Investors VI, L.P. (Director), Green VI Holdings, LLC (Director), Leonard Green & Partners, L.P. (Director), LGP Associates VI-A LLC (Director), LGP Associates VI-B LLC (Director), LGP MANAGEMENT INC (Director) and PERIDOT COINVEST MANAGER LLC (Director).